Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...
Comments
at Cleveland Clinic Suspect as time goes by (and data stays +), it wil...
at Arthritis and Rheumatism Associates, P.C. Excellent points. US rheum drug prices are driven ...
Suspect as time goes by (and data stays +), it wil...
Excellent points. US rheum drug prices are driven ...